Document is current

Article History

Received: 13 January 2022

Accepted: 8 February 2022

First Online: 25 March 2022

Declarations

:

: All animal studies were performed according to protocols approved by the Research Ethical Committee of Fudan University Shanghai Cancer Center. All human subject studies were approved by the institutional review boards of FUSCC, and the trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent before enrollment. Patient samples were collected with written informed consent and ethics approval by the FUSCC Ethics Committee.

: Not applicable

: JZ and XZ are employees of Jiangsu Hengrui Pharmaceuticals (formerly Jiangsu Hengrui Medicine). Other authors have declared that no conflict of interest exists.